Small Molecules
28 February 2013
Lundbeck receives European marketing authorization for Selincro as the first therapy approved for the reduction of alcohol consumption28 February 2013
EnVivo Pharmaceuticals Announces Initiation of Phase 3 Clinical Trial Program of EVP-6124 in Schizophrenia28 February 2013
QRxPharma Resubmits MOXDUO New Drug Application to the FDA28 February 2013
Alchemia Completes Enrolment in Pivotal Phase III HA-Irinotecan Trial of Metastatic Colorectal Cancer28 February 2013
BioLineRx’s EDP-14, for Treatment of Severe and Persistent Asthma, to Enter the Company’s Main Therapeutic Pipeline as BL-901028 February 2013
Novan’s SB204 Could Be First Topical Sebum Inhibitor28 February 2013
Trophos announces positive interim review in pivotal study of olesoxime in Spinal Muscular Atrophy28 February 2013
Boehringer Ingelheim announces initiation of pivotal trial investigating volasertib in patients with acute myeloid leukaemia27 February 2013
Ampio Pharmaceuticals Initiates Clinical Trial of Optina™ in Diabetic Macular Edema (DME): First Patient Dosed27 February 2013
Taiho Pharmaceutical Submits Application for Approval to Manufacture and Market Novel Antitumor Agent TAS-10226 February 2013
Bayer’s Stivarga (regorafenib) Tablets Approved by U.S. FDA for Treatment of Patients with Gastrointestinal Stromal Tumors26 February 2013
AstraZeneca Announces Results From Long-Term Safety Trial Of Naloxegol In Patients With Opioid-Induced Constipation26 February 2013
Boston Therapeutics Reports Positive Phase ll Clinical Trial Results of PAZ320 in Patients With Type 2 Diabetes26 February 2013
Psyadon Pharmaceuticals, Inc. Announces First Patients Enrolled in Phase 3 Study of Ecopipam for the Orphan Indication Lesch-Nyhan Disease25 February 2013
Adynxx Enrolls First Patient in Phase 2 Proof-of-Concept Study for AYX1, Lead Compound for the Prevention of Post-Surgical Pain24 February 2013
Boehringer Ingelheim Presents Efficacy Data for Tiotropium in Symptomatic Asthma Patients in Relation to Allergic Status24 February 2013
VIVUS Receives Decision Regarding Qsiva Appeal24 February 2013
Synthetic Biologics Reports that Flupirtine Sublicensee, Meda AB, to Initiate Phase II Fibromyalgia Clinical Trial in U.S.24 February 2013
Janssen Files First Regulatory Application for Simeprevir (TMC435) for the Treatment of Genotype 1 Hepatitis C Patients in Japan21 February 2013
New findings from two studies support substantial benefit of Pradaxa for prevention of recurrent deep vein thrombosis and pulmonary embolism21 February 2013
GenSpera Announces First Patient Treated in G-202 Phase II Hepatocellular Carcinoma TrialNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports